Frovatriptan chemical structure
Find information on thousands of medical conditions and prescription drugs.

Frova


Frovatriptan (Frova®) is a triptan drug developed by Endo Pharmaceuticals for the treatment of migraine headaches. It is available as 2.5 mg tablets.

Frovatriptan has mean terminal elimination half-life of approximately 26 hours, which is substantially longer than for other triptans.

Frovatriptan is available only by prescription in the United States.



Home
Diseases
Medicines
A
B
C
D
E
F
Captagon
Famohexal
Famotidine
Faslodex
Faslodex
Fasoracetam
Felbamate
Felbatol
Felodipine
Felypressin
Femara
Femara
Fempatch
Femring
Fenfluramine
Fenofibrate
Fentanyl
Fexofenadine
Filgrastim
Filipin
Finasteride
Fioricet
Fiorinal
Flagyl
Flarex
Flavoxate
Flecainide
Flexeril
Flomax
Flonase
Flovent
Floxuridine
Fluacizine
Flucloxacillin
Fluconazole
Flucytosine
Fludarabine
Fludrocortisone
Flumazenil
Flunisolide
Flunitrazepam
Fluocinonide
Fluohexal
Fluorometholone
Fluorouracil
Fluoxetine
Fluphenazine
Flurazepam
Flutamide
Fluticasone
Fluvastatin
Fluvoxamine
FML
Focalin
Folic acid
Follutein
Fomepizole
Formoterol
Fortamet
Fortovase
Fosamax
Fosinopril
Fosinoprilat
Fosmidomycin
Fosphenytoin
Frova
Frovatriptan
Frusehexal
Fulvestrant
Fumagillin
Furazolidone
Furosemide
Furoxone
Fusafungine
Fusidic acid
Fuzeon
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Triptan may help prevent menstrual migraine - Study of 545 Women
From OB/GYN News, 7/15/03 by Robert Finn

HONOLULU -- Frovatriptan prevented menstrually associated migraine headaches in 50% of those who took a twice-daily dose during the perimenstrual period, in a study of 545 women.

"This is the first time we've seen a triptan actually prevent these headaches in such a large number of women before they experience pain," Dr. Stephen Silberstein said at the annual meeting of the American Academy of Neurology.

He acknowledged receiving grant support and honoraria from, and serving as a consultant to, Elan Pharmaceuticals Inc., which markets frovatriptan under the brand name Frova.

The double-blind, placebo-controlled, triple-crossover study involved 545 women, mean age 37.6 years, who had had an average of 11.4 menstrual migraine attacks over the past 12 months. Patients were randomized to one of six treatment sequences, in which successive perimenstrual periods were treated with placebo, frovatriptan 2.5 mg once daily, and frovatriptan 2.5 mg twice daily. They took the medication for a total of 6 days each month, beginning 2 days before they expected a menstrually associated migraine to begin, said Dr. Silberstein, director of the Jefferson Headache Clinic at Thomas Jefferson University Hospital in Philadelphia.

Menstrually associated migraine was absent during the 6-day period in 50% of those taking frovatriptan twice daily, 39% of those taking frovatriptan once daffy, and 26% of those taking placebo. On this measure, both doses of frovatriptan were significantly better than placebo, and the higher dose of frovatriptan was significantly better than the lower dose.

COPYRIGHT 2003 International Medical News Group
COPYRIGHT 2003 Gale Group

Return to Frova
Home Contact Resources Exchange Links ebay